Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Anti-Bacterial Agents | 12 | 2019 | 10083 | 0.76 | Why? |
| Drug Resistance, Microbial | 2 | 2019 | 419 | 0.67 | Why? |
| Drug Utilization | 3 | 2019 | 619 | 0.65 | Why? |
| Developed Countries | 1 | 2018 | 500 | 0.55 | Why? |
| beta-Lactams | 1 | 2017 | 210 | 0.55 | Why? |
| Drug Prescriptions | 2 | 2019 | 1062 | 0.50 | Why? |
| Child Development | 1 | 2017 | 352 | 0.48 | Why? |
| Amoxicillin | 4 | 2018 | 98 | 0.43 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.42 | Why? |
| Commerce | 1 | 2018 | 1109 | 0.37 | Why? |
| Sepsis | 3 | 2018 | 3517 | 0.32 | Why? |
| Pneumonia | 2 | 2020 | 5652 | 0.26 | Why? |
| Clinical Trials as Topic | 3 | 2017 | 7330 | 0.26 | Why? |
| Developing Countries | 1 | 2018 | 4283 | 0.24 | Why? |
| Health Care Surveys | 4 | 2020 | 2942 | 0.24 | Why? |
| Infant, Newborn | 14 | 2021 | 23105 | 0.24 | Why? |
| Switzerland | 5 | 2021 | 2738 | 0.23 | Why? |
| Antimicrobial Stewardship | 3 | 2019 | 931 | 0.22 | Why? |
| Betamethasone | 1 | 2020 | 63 | 0.22 | Why? |
| Penicillins | 2 | 2019 | 132 | 0.21 | Why? |
| World Health Organization | 5 | 2020 | 4213 | 0.21 | Why? |
| Practice Patterns, Physicians' | 2 | 2018 | 4927 | 0.21 | Why? |
| Child, Hospitalized | 2 | 2020 | 556 | 0.20 | Why? |
| Child | 19 | 2021 | 70012 | 0.19 | Why? |
| Administration, Oral | 4 | 2019 | 2340 | 0.19 | Why? |
| Pharmacopoeias as Topic | 1 | 2017 | 8 | 0.18 | Why? |
| Drug Resistance, Bacterial | 2 | 2018 | 1414 | 0.18 | Why? |
| Asthma | 1 | 2017 | 4383 | 0.18 | Why? |
| Child, Preschool | 14 | 2021 | 36283 | 0.18 | Why? |
| Drug Labeling | 1 | 2017 | 65 | 0.17 | Why? |
| Drugs, Essential | 1 | 2018 | 117 | 0.16 | Why? |
| Neonatal Sepsis | 1 | 2017 | 69 | 0.16 | Why? |
| Bronchiolitis | 1 | 2020 | 297 | 0.16 | Why? |
| Antibiotic Prophylaxis | 1 | 2019 | 399 | 0.15 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.15 | Why? |
| Child Day Care Centers | 1 | 2018 | 208 | 0.15 | Why? |
| Infant | 12 | 2021 | 30274 | 0.15 | Why? |
| Crowding | 1 | 2021 | 731 | 0.14 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.14 | Why? |
| Guideline Adherence | 2 | 2018 | 2309 | 0.14 | Why? |
| Guidelines as Topic | 4 | 2020 | 2844 | 0.14 | Why? |
| Pediatrics | 2 | 2020 | 2969 | 0.13 | Why? |
| Europe | 3 | 2020 | 12702 | 0.13 | Why? |
| Inappropriate Prescribing | 1 | 2017 | 284 | 0.13 | Why? |
| Return to Work | 1 | 2020 | 579 | 0.13 | Why? |
| Multicenter Studies as Topic | 1 | 2020 | 2437 | 0.13 | Why? |
| Communicable Diseases | 2 | 2019 | 2148 | 0.13 | Why? |
| Pneumococcal Vaccines | 1 | 2019 | 571 | 0.13 | Why? |
| Housing | 1 | 2021 | 1146 | 0.12 | Why? |
| Off-Label Use | 1 | 2017 | 553 | 0.12 | Why? |
| Risk Management | 1 | 2020 | 1044 | 0.12 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2017 | 398 | 0.12 | Why? |
| Urinary Tract Infections | 1 | 2017 | 534 | 0.11 | Why? |
| Pneumonia, Bacterial | 1 | 2018 | 843 | 0.11 | Why? |
| Program Development | 1 | 2017 | 1089 | 0.11 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.11 | Why? |
| Dose-Response Relationship, Drug | 2 | 2017 | 3776 | 0.11 | Why? |
| Anti-Infective Agents | 2 | 2019 | 1766 | 0.10 | Why? |
| Clinical Protocols | 1 | 2020 | 2734 | 0.09 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2017 | 1115 | 0.09 | Why? |
| Data Collection | 1 | 2017 | 1769 | 0.09 | Why? |
| Microbial Sensitivity Tests | 1 | 2017 | 2886 | 0.09 | Why? |
| Humans | 30 | 2021 | 930598 | 0.08 | Why? |
| Drug Dosage Calculations | 2 | 2019 | 243 | 0.08 | Why? |
| Hemorrhagic Fever, Ebola | 1 | 2018 | 1475 | 0.08 | Why? |
| Immunization Programs | 1 | 2019 | 2006 | 0.08 | Why? |
| Research | 1 | 2019 | 2115 | 0.08 | Why? |
| Community-Acquired Infections | 1 | 2018 | 2328 | 0.08 | Why? |
| Communicable Diseases, Emerging | 1 | 2020 | 2523 | 0.08 | Why? |
| Inpatients | 2 | 2018 | 5161 | 0.07 | Why? |
| Communicable Disease Control | 3 | 2020 | 29620 | 0.07 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.07 | Why? |
| Adolescent | 9 | 2021 | 86841 | 0.07 | Why? |
| Global Health | 2 | 2018 | 13911 | 0.07 | Why? |
| Treatment Outcome | 3 | 2020 | 51732 | 0.07 | Why? |
| Prospective Studies | 2 | 2020 | 43301 | 0.06 | Why? |
| Genome, Viral | 2 | 2021 | 13157 | 0.06 | Why? |
| Hospitals | 2 | 2021 | 11793 | 0.06 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.06 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.06 | Why? |
| Triage | 1 | 2020 | 7151 | 0.05 | Why? |
| Contact Tracing | 1 | 2021 | 8448 | 0.05 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.05 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.05 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.05 | Why? |
| Penicillin V | 1 | 2019 | 10 | 0.05 | Why? |
| Respiratory Tract Infections | 1 | 2020 | 6817 | 0.05 | Why? |
| Prevalence | 2 | 2019 | 25773 | 0.05 | Why? |
| Disease Transmission, Infectious | 2 | 2020 | 9044 | 0.05 | Why? |
| Gentamicins | 1 | 2018 | 76 | 0.05 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.05 | Why? |
| Biomedical Research | 1 | 2019 | 5270 | 0.05 | Why? |
| Sierra Leone | 1 | 2018 | 267 | 0.04 | Why? |
| Fosfomycin | 1 | 2017 | 48 | 0.04 | Why? |
| Bronchoalveolar Lavage | 1 | 2020 | 603 | 0.04 | Why? |
| Male | 11 | 2021 | 367725 | 0.04 | Why? |
| Tonsillitis | 1 | 2017 | 67 | 0.04 | Why? |
| Vaccines, Conjugate | 1 | 2019 | 328 | 0.04 | Why? |
| Tonsillectomy | 1 | 2017 | 115 | 0.04 | Why? |
| Cephalosporins | 1 | 2018 | 250 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.04 | Why? |
| Injections, Intramuscular | 1 | 2018 | 800 | 0.04 | Why? |
| beta-Lactam Resistance | 1 | 2017 | 150 | 0.04 | Why? |
| Absenteeism | 1 | 2018 | 287 | 0.04 | Why? |
| Cross Infection | 1 | 2018 | 8675 | 0.04 | Why? |
| Interrupted Time Series Analysis | 1 | 2019 | 868 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.04 | Why? |
| Colistin | 1 | 2017 | 217 | 0.03 | Why? |
| Female | 9 | 2021 | 380317 | 0.03 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2017 | 214 | 0.03 | Why? |
| Adult | 5 | 2021 | 244371 | 0.03 | Why? |
| Disease Outbreaks | 2 | 2018 | 27595 | 0.03 | Why? |
| History, 20th Century | 1 | 2019 | 1282 | 0.03 | Why? |
| Oropharynx | 1 | 2020 | 1581 | 0.03 | Why? |
| Body Weight | 1 | 2017 | 1074 | 0.03 | Why? |
| Pharmacy Service, Hospital | 1 | 2019 | 645 | 0.03 | Why? |
| Ebolavirus | 1 | 2018 | 834 | 0.03 | Why? |
| beta-Lactamases | 1 | 2017 | 759 | 0.03 | Why? |
| Program Evaluation | 1 | 2019 | 1929 | 0.03 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.02 | Why? |
| Child Health | 1 | 2018 | 940 | 0.02 | Why? |
| Hospitals, Pediatric | 1 | 2019 | 1792 | 0.02 | Why? |
| Nucleocapsid Proteins | 1 | 2020 | 3120 | 0.02 | Why? |
| Viral Envelope Proteins | 1 | 2020 | 3539 | 0.02 | Why? |
| Aftercare | 1 | 2017 | 1637 | 0.02 | Why? |
| Age Factors | 2 | 2019 | 21039 | 0.02 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2021 | 8811 | 0.02 | Why? |
| Cross-Sectional Studies | 3 | 2019 | 53120 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| Poverty | 1 | 2017 | 2302 | 0.02 | Why? |
| England | 1 | 2017 | 5116 | 0.02 | Why? |
| Outpatients | 1 | 2018 | 3417 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2019 | 7268 | 0.02 | Why? |
| Parents | 1 | 2018 | 2758 | 0.02 | Why? |
| Middle Aged | 4 | 2021 | 270681 | 0.01 | Why? |
| Mobile Applications | 1 | 2017 | 3032 | 0.01 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.01 | Why? |
| Mass Screening | 1 | 2021 | 8005 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.01 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.01 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.01 | Why? |
| Internet | 1 | 2017 | 6204 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.01 | Why? |
| United Kingdom | 1 | 2019 | 18046 | 0.01 | Why? |
| Masks | 1 | 2021 | 8528 | 0.01 | Why? |
| Physicians | 1 | 2017 | 4214 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.01 | Why? |
| Hospitalization | 2 | 2019 | 54280 | 0.01 | Why? |
| Registries | 1 | 2017 | 12327 | 0.01 | Why? |
| Incidence | 1 | 2019 | 25622 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| Aged | 2 | 2021 | 215776 | 0.01 | Why? |
| Quarantine | 1 | 2021 | 18418 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |
| Risk Factors | 1 | 2018 | 71621 | 0.01 | Why? |
| Retrospective Studies | 1 | 2018 | 105322 | 0.00 | Why? |
Bielicki's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(163)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(112)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_